Drug Trial Radar · NCT06672146
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help more patients with the IDH2 gene get rid of AML. ASTX727 is a fixed-dose formulation of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Enasidenib works by stopping the growth and spread of tumor cells that have the IDH2 mutation. Giving ASTX727 and venetoclax plus enasidenib may work better in treating AML patients with the IDH2 mutation.
Conditions
- Acute Myeloid Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Decitabine and CedazuridineDrug
Given PO
EnasidenibDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal residual disease negative (MRDneg) complete remission (CR) rateTime frame: Baseline to 5 years
Locations
138 sites in 2 countries. Site status is shown where the registry gives one.
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Active not recruiting
UCSF Medical Center-Parnassus
San Francisco, California · Recruiting
Mills Health Center
San Mateo, California · Active not recruiting
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida · Suspended
Miami Cancer Institute
Miami, Florida · Recruiting
Memorial Hospital West
Pembroke Pines, Florida · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois · Recruiting
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois · Recruiting
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois · Recruiting
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois · Recruiting
Edward Hines Jr VA Hospital
Hines, Illinois · Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Recruiting
Northwestern Medicine Orland Park
Orland Park, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
UChicago Medicine Northwest Indiana
Crown Point, Indiana · Recruiting
University of Kansas Clinical Research Center
Fairway, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.